scholarly journals THE VALUE OF ACUTE RESPIRATORY VIRAL INFECTIONS IN THE DEVELOPMENT OF CHRONIC HEART FAILURE DISEASE IN CHILDREN

2012 ◽  
Vol 17 (3) ◽  
pp. 42-46 ◽  
Author(s):  
T. A. Ruzhentsova ◽  
A. V Gorelov
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Viral Infections ◽  
Laboratory Features ◽  
Respiratory Viral Infections ◽  
One Year

The data on clinical, ECG, ultrasound and laboratory features of myocarditides that developed in children with acute respiratory viral infections (ARVI) have been presented in this article. The dynamics of changes and the identified possibility of forming the chronic pathology in a one year after the onset of the disease has been shown.

scholarly journals Clinical efficacy of acute respiratory viral infections prevention in patients with chronic heart failure

2019 ◽  
Vol 91 (3) ◽  
pp. 36-41 ◽  
Author(s):  
A V Budnevsky ◽  
A D Shurupova ◽  
A Ya Kravchenko ◽  
R E Tokmachev
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Standard Therapy ◽  
Hospital Admissions ◽  
Viral Infections ◽  
Clinical Course ◽  
Functional Class ◽  
Dynamic Monitoring ◽  
Interferon Inducer ◽  
Respiratory Viral Infections

The aim of the study was to evaluate the ARVI prevention effectiveness in patients with chronic heart failure (CHF) using interferon inducer amixin. Materials and methods. Conducted a comprehensive survey, dynamic monitoring and treatment of 60 patients aged from 49 to 70 years (mean age 60.25±4.57 years, 17 men and 43 women) with CHF with preserved ejection fraction of left ventricle (LVEF) (≥50%), II-III functional class (FC) according to the classification of new York Heart Association (NYHA), which developed as a result of coronary heart disease (CHD), hypertensive disease (HD). Of these, 30 patients (group 1) on the background of standard therapy for CHF received for the prevention of ARVI tiloron (Amixin) at a dose of 125 mg once a week for 6 weeks, two courses for 1 year. Group 2 patients received only standard therapy for CHF. Results. A decrease in the frequency of ARVI in patients with CHF treated with Amixin was found, which was accompanied by a decrease in the severity of subclinical inflammation by reducing the production of proinflammatory (IL-1β) and increasing the production of anti-inflammatory (IL-10) cytokines, reducing neurohumoral activation (reducing levels of aldosterone and Nt-proBNP), increasing the level of α- and γ-interferon. The positive dynamics of biomarkers of systemic inflammation and neurohormonal activation explains the improvement of the clinical course in patients with CHF (increase of tolerance to physical loads, reducing the number of visits to General practitioner and hospital admissions in the hospital during 12 months of observation). Conclusion. A promising approach to the prevention of SARS in patients with CHF is course therapy with Amixin (2 times a year before the seasonal rising in the incidence of respiratory viral infections and influenza), which allows to achieve both decreasing in the frequency of SARS per year, and improvement the clinical course of CHF.

scholarly journals 195. Economic and Clinical Burden of Respiratory Virus Infections in Allogeneic Hematopoietic Cell Transplantation Recipients

2020 ◽  
Vol 7 (Supplement_1) ◽  
pp. S226-S226
Author(s):  
Michael G Ison ◽  
Nelson Chao ◽  
Francisco M Marty ◽  
Seung Hyun Moon ◽  
Zhiji Zhang ◽  
...  
Keyword(s):  
Resource Utilization ◽  
Research Study ◽  
Viral Infections ◽  
Scientific Research ◽  
Health Resource ◽  
Health Resource Utilization ◽  
Allogeneic Hct ◽  
Study Investigator ◽  
Respiratory Viral Infections ◽  
One Year

Abstract Background Respiratory viruses (RV), including respiratory syncytial virus (RSV), influenza, parainfluenza virus (PIV), and human metapneumovirus (HMPV), frequently lead to serious complications such as lower respiratory tract infections and death in allogeneic hematopoietic cell transplantation (HCT) recipients. We used a large US claims database to compare the total reimbursement (TR), health resource utilization (HRU) and clinical outcomes between HCT patients with and without RV infections (RVI). Methods We used the Decision Resources Group Real World Evidence Data Repository to identify HCT recipients with date of service for the procedure from 1/1/2012-12/31/2017. We estimated the reimbursements from submitted charges using a reimbursement to charge ratio of 0.425. We examined the study outcomes in the year following HCT in patients with and without RVI. We also used a generalized linear model to determine adjusted TR stratified by the presence or absence of any acute or chronic graft-versus-host diseases (GVHD) after adjusting for age, health plan, underlying disease, stem cell source, number of comorbidities, baseline costs, and follow-up time. Results The study included 13,363 patients, representing 22% of HCTs reported to CIBMTR for the study period, of which 1,368 (10%) were coded with an RVI in the year following HCT: 578 (4%) RSV, 687 (5%) influenza, 166 (1%) PIV, and 181 (1%) HMPV. Unadjusted median TR were $132,395 higher for any RVI ($139,439 RSV, $101,963 influenza, $185,041 PIV and $248,029 HMPV) compared to those without RVI (Table 1). Adjusted TR were significantly higher for patients with any RVI compared to patients without that infection (p< .01) with or without GVHD (Figure 1). Patients with any RVI had significantly longer length of stay (LOS) for the HCT hospitalization, readmission rate and LOS after HCT hospitalization compared to patients without RVI (p< 0.05) (Table 2). A significantly higher proportion of patients with any RVI had pneumonia as compared to patients without that infection, irrespective of presence of GVHD (p< .0001). Table 1: Total healthcare reimbursement within one year of undergoing allogeneic HCT for patients with and without respiratory viral infections Figure 1: Adjusted total reimbursements within one year of undergoing allogeneic HCT for patients with and without respiratory viral infections Table 2: Health resource utilization within one year of undergoing allogeneic HCT for patients with and without respiratory viral infections Conclusion Allogeneic HCT patients with RVI have a significantly higher burden of TR, health resource utilization and worse clinical outcomes such as pneumonia during one year of undergoing HCT, regardless of the presence of GVHD. Disclosures Michael G. Ison, MD MS, AlloVir (Consultant) Francisco M. Marty, MD, Allovir (Consultant)Amplyx (Consultant)Ansun (Scientific Research Study Investigator)Avir (Consultant)Cidara (Scientific Research Study Investigator)F2G (Consultant, Scientific Research Study Investigator)Kyorin (Consultant)Merck (Consultant, Grant/Research Support, Scientific Research Study Investigator)New England Journal of Medicine (Other Financial or Material Support, Honorarium for Video)Regeneron (Consultant, Scientific Research Study Investigator)ReViral (Consultant)Scynexis (Scientific Research Study Investigator)Symbio (Consultant)Takeda (Scientific Research Study Investigator)United Medical (Consultant)WHISCON (Scientific Research Study Investigator) Seung Hyun Moon, MD, MPA, AlloVir (Employee, Shareholder) Zhiji Zhang, MS, AlloVir (Independent Contractor) Aastha Chandak, PhD, AlloVir (Independent Contractor)

Abstract 3143: Reverse Hemodynamic Remodelling May Be Possible Over Time

Circulation ◽  
2007 ◽  
Vol 116 (suppl_16) ◽  
Author(s):  
Lynne W Stevenson ◽  
Yong K Cho ◽  
J. T Heywood ◽  
Robert C Bourge ◽  
William T Abraham ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Pulmonary Artery ◽  
Right Ventricular ◽  
Nyha Class ◽  
Systolic Pressure ◽  
Filling Pressure ◽  
Class Iii ◽  
One Year ◽  
Over Time

Introduction : Elevated filling pressures are a hallmark of chronic heart failure. They can be reduced acutely during HF hospitalization but the hemodynamic impact of ongoing therapy to maintain optivolemia has not been established. Methods and Results : After recent HF hospitalization, 274 NYHA Class III or IV HF patients were enrolled in the COMPASS-HF study at 28 experienced HF centers and received intense HF management (average 24.7 staff contacts/ 6 months) ± access to filling pressure information to adjust diuretics to maintain optivolemia, usually defined as estimated pulmonary artery diastolic (PAD) pressure of 12±4 mmHg. Filling pressure information was available for half the patients during the first 6 months (the Chronicle group, <Access), and for all patients during the next 6 months. Diuretics were adjusted 12.7 times per patient in the Chronicle group and 8.2 times per patient in the Control (-Access) group during the first 6 months (p = 0.0001). Compared to baseline, decreases in RV systolic pressure (RVSP) and ePAD were significant for the +Access patients by one year (p=0.0012 and p =.04, respectively). The Control patients exhibited a similar trend 6 months after crossing to +Access (figure ). Conclusions: Targeted therapeutic adjustments, based on continuous filling pressures along with intensification of HF management contacts, are associated with a reduction in chronic left-sided filling pressures and right ventricular load.

scholarly journals A Multiparametric Approach Based on NT-proBNP, ST2, and Galectin3 for Stratifying One Year Prognosis of Chronic Heart Failure Outpatients

2017 ◽  
Vol 4 (3) ◽  
pp. 0009 ◽  
Author(s):  
Dario Grande ◽  
Marta Leone ◽  
Caterina Rizzo ◽  
Paola Terlizzese ◽  
Giuseppe Parisi ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
One Year

scholarly journals Respiratory viral infections do not explain the winter peak in heart failure

Respirology ◽  
2021 ◽  
Author(s):  
Catherina L. Chang ◽  
Robert J. Hancox ◽  
Chris Mansell ◽  
Sarah M. Fairweather ◽  
Eskandarain Shafuddin
Keyword(s):  
Heart Failure ◽  
Viral Infections ◽  
Winter Peak ◽  
Respiratory Viral Infections

Adjunctive therapy with low-molecular-weight heparin in patients with chronic heart failure secondary to dilated cardiomyopathy: One-year follow-up results of the randomized trial

2006 ◽  
Vol 152 (4) ◽  
pp. 713.e1-713.e7 ◽  
Author(s):  
Romuald Wojnicz ◽  
Jolanta Nowak ◽  
Bożena Szyguła-Jurkiewicz ◽  
Krzysztof Wilczek ◽  
Andrzej Lekston ◽  
...  
Keyword(s):  
Heart Failure ◽  
Molecular Weight ◽  
Chronic Heart Failure ◽  
Dilated Cardiomyopathy ◽  
Randomized Trial ◽  
Adjunctive Therapy ◽  
Low Molecular Weight Heparin ◽  
Low Molecular Weight ◽  
One Year

scholarly journals To the Issue of Acute Myocarditis

2019 ◽  
Vol 5 (4) ◽  
pp. 108-112
Author(s):  
E. Mokina ◽  
E. Naumenko ◽  
D. Kumanyaeva ◽  
M. Rakhmatullina ◽  
E. Surgaeva
Keyword(s):  
Heart Failure ◽  
Cardiovascular System ◽  
Viral Infections ◽  
Acute Myocarditis ◽  
Controversial Issues ◽  
Historical Aspect ◽  
Respiratory Viral Infections ◽  
Additional Therapy

According to statistics, pathology of the cardiovascular system can occur in 80% of patients who have undergone various acute viral infections, including influenza. All these manifestations are compensatory in nature and are completed independently without additional therapy. Children have respiratory viral infections, arising heart failure and various rhythm disturbances, quite often with a protracted course. Perhaps the emergence of an acute process, as well as the presence of viruses that can cause difficulties in terms of diagnosis and diagnosis, and other controversial issues. This attempt to highlight some controversial points. The detailed historical aspect of the formation of this nosological unit.

scholarly journals Benefit of Ambulatory Management of Patients with Chronic Heart Failure by Protocolized Follow-Up Therapeutic Education and Remote Monitoring Solution: An Original Study in 159 Patients

2020 ◽  
Vol 9 (10) ◽  
pp. 3106
Author(s):  
Anne Jenneve ◽  
Noel Lorenzo-Villalba ◽  
Guy Courdier ◽  
Samy Talha ◽  
François Séverac ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Education Program ◽  
Remote Monitoring ◽  
Therapeutic Education ◽  
Left Ventricular Ejection ◽  
The Mean ◽  
One Year ◽  
Heart Condition

This study sought to determine whether the implementation of regular and structured follow-up of patients with chronic heart failure (CHF), combined with therapeutic education and remote monitoring solution, leads to better management. This was a single-center retrospective study conducted in a cohort of patients with proven CHF who were followed up in the Mulhouse region (France) between January 2016 and December 2017 by the Unité de Suivi des Patients Insuffisants Cardiaques (USICAR) unit. These patients received regular protocolized follow-up, a therapeutic education program, and several used a telemedicine platform for a two-year period. The primary endpoint was the number of days hospitalized for heart failure (HF) per patient per year. The main secondary endpoints included the number of days hospitalized for a heart condition other than HF and the number of hospital stays for HF per patient. These endpoints were collected during the year preceding enrollment, at one year of follow-up, and at two years of follow-up. The remote monitoring solution was evaluated on the same criterion. Overall, 159 patients with a mean age of 72.9 years were included in this study. They all had CHF, mainly NYHA Class I-II (88.7%), predominantly of ischemic origin (50.9%), and with altered left ventricular ejection fraction in 69.2% of cases. The mean number of days hospitalized for HF per patient per year was 8.33 (6.84–10.13) in the year preceding enrollment, 2.6 (1.51–4.47) at one year of follow-up, and 2.82 at two years of follow-up (1.30–6.11) (p < 0.01 for both comparisons). The mean number of days hospitalized for a heart condition other than HF was 1.73 (1.16–2.6), 1.81 (1.04–3.16), and 1.32 (0.57–3.08), respectively (p = ns). The percentage of hospitalization for HF for each patient was 69.5% (60.2–77.4), 16.2% (10–25.2), and 19.3% (11–31.8), respectively (p < 0.001 for both comparisons). In the group telemedicine, the mean number of days hospitalized for HF per patient per year was 8.33 during the year preceding enrollment, 2.3 during the first year of follow-up, and 1.7 during the second. This difference was significant (p < 0.001). The “number of days hospitalized for a heart condition other than HF” was significantly reduced in the group of patient’s beneficiating from the remote monitoring solution. This study demonstrates the value of a protocolized follow-up associated with a therapeutic optimization, therapeutic education program, and the use of a remote monitoring solution to improve the management of ambulatory patients with CHF, particularly of moderate severity.

Sign in / Sign up

Export Citation Format

Share Document